ストックスクリーナーアプリを入手
5.42
7.03%
-0.41
プレマーケット:
5.41
-0.010
-0.18%
前日終値:
$5.83
開ける：
$5.63
24時間の取引高:
638.00K
Relative Volume:
0.84
時価総額：
$406.19M
収益：
$46.02M
当期純損益:
$-70.80M
株価収益率:
-2.978
EPS:
-1.82
ネットキャッシュフロー:
$-1.61M
1週間 パフォーマンス:
-14.51%
1か月 パフォーマンス:
-13.56%
6か月 パフォーマンス:
-32.17%
1年 パフォーマンス:
-73.78%
1日の値動き範囲:
$5.34
$5.71
1週間の範囲:
$5.34
$6.4811
52週間の値動き範囲:
$5.34
$23.64
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
名前
Eyepoint Pharmaceuticals Inc
セクター
電話
617-926-5000
住所
480 PLEASANT STREET, WATERTOWN, MA
EYPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
5.42 | 406.19M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-07 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-22 | 開始されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Mizuho | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2021-01-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-06 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 再開されました | Laidlaw | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
すべてを表示
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan
What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World
(EYPT) Investment Report - news.stocktradersdaily.com
Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia
Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target - Investing.com India
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k - Yahoo Finance
EyePoint Pharmaceuticals: Q4 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highli - GuruFocus.com
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
EyePoint Pharmaceuticals Reports 2024 Financial Results - TipRanks
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss - Investing.com India
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals Q4 2024 Earnings: Revenue Beats at $11. - GuruFocus.com
EYEPOINT PHARMACEUTICALS Earnings Results: $EYPT Reports Quarterly Earnings - Nasdaq
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat - Investing.com
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Pharmaceuticals, Inc. Q4 Loss Increases, Misses Estimates - Nasdaq
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns? - StockTitan
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result - Yahoo Finance
Eyepoint Announces Participation At Upcoming Investor Conferences - MENAFN.COM
EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Nasdaq
How to Watch EyePoint's March Presentations at Two Major Healthcare Investment Conferences - StockTitan
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Brokerages - Defense World
EyePoint Pharmaceuticals (EYPT) Projected to Post Earnings on Wednesday - MarketBeat
(EYPT) Technical Pivots with Risk Controls - Stock Traders Daily
Eyepoint Pharmaceuticals Inc (EYPT) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):